Estonie - estonien - Ravimiamet

aurobindo pharma limited - paroksetiin - õhukese polümeerikattega tablett - 20mg 30tk; 20mg 60tk; 20mg 100tk; 20mg 10tk; 20mg 98tk; 20mg 50tk; 20mg 28tk; 20mg 20tk; 20mg 7tk

Estonie - estonien - Ravimiamet

aurobindo pharma limited - paroksetiin - õhukese polümeerikattega tablett - 30mg 30tk; 30mg 100tk; 30mg 250tk; 30mg 14tk; 30mg 50tk; 30mg 28tk; 30mg 10tk; 30mg 20tk; 30mg 98tk; 30mg 56tk

Union européenne - estonien - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Union européenne - estonien - EMA (European Medicines Agency)

basilea pharmaceutica deutschland gmbh - isavukonasool - aspergilloos - cresemba on näidustatud täiskasvanute raviks:invasiivsed aspergillosismucormycosis patsientidel, kellele amphotericin b on inappropriateconsideration tuleb arvestada ametlikke juhiseid sobiva kasutamise kohta seentevastased ained.

Union européenne - estonien - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Estonie - estonien - Ravimiamet

sun pharmaceutical industries europe b.v. - lopinaviir+ritonaviir - õhukese polümeerikattega tablett - 200mg+50mg 120tk; 200mg+50mg 360tk

Estonie - estonien - Ravimiamet

aurobindo pharma (malta) limited - omeprasool - gastroresistentne kõvakapsel - 10mg 98tk; 10mg 7tk; 10mg 28tk; 10mg 60tk; 10mg 14tk; 10mg 500tk; 10mg 30tk

Estonie - estonien - Ravimiamet

aurobindo pharma (malta) limited - omeprasool - gastroresistentne kõvakapsel - 40mg 50tk; 40mg 30tk; 40mg 500tk; 40mg 28tk; 40mg 7tk; 40mg 100tk; 40mg 60tk; 40mg 98tk; 40mg 14tk; 40mg 15tk; 40mg 56tk

Estonie - estonien - Ravimiamet

aurobindo pharma limited - mirtasapiin - suus dispergeeruv tablett - 15mg 30tk; 15mg 96tk; 15mg 48tk; 15mg 90tk

Estonie - estonien - Ravimiamet

aurobindo pharma limited - amoksitsilliin+klavulaanhape - õhukese polümeerikattega tablett - 875mg+125mg 4tk; 875mg+125mg 6tk; 875mg+125mg 12tk; 875mg+125mg 8tk; 875mg+125mg 20tk; 875mg+125mg 16tk; 875mg+125mg 7tk; 875mg+125mg 25tk; 875mg+125mg 21tk; 875mg+125mg 5tk; 875mg+125mg 50tk; 875mg+125mg 40tk; 875mg+125mg 100tk; 875mg+125mg 14tk; 875mg+125mg 24tk; 875mg+125mg 30tk